- Home
- TRUE vs IPHA Comparison
TRUE vs IPHA Comparison
Compare TRUE & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUE
- IPHA
- Stock Information
- Founded
- TRUE 2005
- IPHA 1999
- Country
- TRUE United States
- IPHA France
- Employees
- TRUE N/A
- IPHA N/A
- Industry
- TRUE Computer Software: Programming Data Processing
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- TRUE Technology
- IPHA Health Care
- Exchange
- TRUE Nasdaq
- IPHA Nasdaq
- Market Cap
- TRUE 175.1M
- IPHA 160.1M
- IPO Year
- TRUE 2014
- IPHA 2019
- Fundamental
- Price
- TRUE $1.60
- IPHA N/A
- Analyst Decision
- TRUE Hold
- IPHA Hold
- Analyst Count
- TRUE 5
- IPHA 2
- Target Price
- TRUE $3.33
- IPHA $2.00
- AVG Volume (30 Days)
- TRUE 348.8K
- IPHA 20.0K
- Earning Date
- TRUE 11-05-2025
- IPHA 09-17-2025
- Dividend Yield
- TRUE N/A
- IPHA N/A
- EPS Growth
- TRUE N/A
- IPHA N/A
- EPS
- TRUE N/A
- IPHA N/A
- Revenue
- TRUE $184,559,000.00
- IPHA $14,839,695.00
- Revenue This Year
- TRUE $8.42
- IPHA $350.96
- Revenue Next Year
- TRUE $5.64
- IPHA $32.92
- P/E Ratio
- TRUE N/A
- IPHA N/A
- Revenue Growth
- TRUE 11.66
- IPHA N/A
- 52 Week Low
- TRUE $1.05
- IPHA $1.29
- 52 Week High
- TRUE $4.62
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- TRUE 35.47
- IPHA 48.26
- Support Level
- TRUE $1.51
- IPHA $1.95
- Resistance Level
- TRUE $1.89
- IPHA $2.10
- Average True Range (ATR)
- TRUE 0.13
- IPHA 0.07
- MACD
- TRUE -0.07
- IPHA 0.02
- Stochastic Oscillator
- TRUE 8.54
- IPHA 55.33
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.